HK1257170A1 - 二氫吲哚-2-酮衍生物 - Google Patents
二氫吲哚-2-酮衍生物Info
- Publication number
- HK1257170A1 HK1257170A1 HK18116051.2A HK18116051A HK1257170A1 HK 1257170 A1 HK1257170 A1 HK 1257170A1 HK 18116051 A HK18116051 A HK 18116051A HK 1257170 A1 HK1257170 A1 HK 1257170A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- indolin
- derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15193342 | 2015-11-06 | ||
PCT/EP2016/076332 WO2017076852A1 (en) | 2015-11-06 | 2016-11-02 | Indolin-2-one derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1257170A1 true HK1257170A1 (zh) | 2019-10-18 |
Family
ID=54476820
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18116051.2A HK1257170A1 (zh) | 2015-11-06 | 2018-12-13 | 二氫吲哚-2-酮衍生物 |
Country Status (34)
Country | Link |
---|---|
US (2) | US10710985B2 (zh) |
EP (1) | EP3371168B1 (zh) |
JP (1) | JP6857662B2 (zh) |
KR (1) | KR20180080305A (zh) |
CN (1) | CN108349944B (zh) |
AR (1) | AR106588A1 (zh) |
AU (1) | AU2016348493B2 (zh) |
BR (1) | BR112018008056A2 (zh) |
CA (1) | CA3002489C (zh) |
CL (1) | CL2018001085A1 (zh) |
CO (1) | CO2018005718A2 (zh) |
CR (1) | CR20180255A (zh) |
DK (1) | DK3371168T3 (zh) |
ES (1) | ES2808920T3 (zh) |
HK (1) | HK1257170A1 (zh) |
HR (1) | HRP20201158T1 (zh) |
HU (1) | HUE050083T2 (zh) |
IL (1) | IL258656A (zh) |
LT (1) | LT3371168T (zh) |
MA (1) | MA43159B1 (zh) |
MX (1) | MX2018005121A (zh) |
MY (1) | MY197370A (zh) |
PE (1) | PE20181885A1 (zh) |
PH (1) | PH12018500978A1 (zh) |
PL (1) | PL3371168T3 (zh) |
PT (1) | PT3371168T (zh) |
RS (1) | RS60504B1 (zh) |
RU (1) | RU2727179C2 (zh) |
SG (1) | SG11201803796SA (zh) |
SI (1) | SI3371168T1 (zh) |
TW (1) | TWI631117B (zh) |
UA (1) | UA122589C2 (zh) |
WO (1) | WO2017076852A1 (zh) |
ZA (1) | ZA201802411B (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108137561B (zh) | 2015-11-06 | 2021-03-26 | 豪夫迈·罗氏有限公司 | 二氢吲哚-2-酮衍生物 |
EP3371170B1 (en) | 2015-11-06 | 2019-07-31 | H. Hoffnabb-La Roche Ag | Indolin-2-one derivatives useful in the treatment of cns diseases |
JP6857653B2 (ja) | 2015-11-06 | 2021-04-14 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Cns及び関連障害の治療において使用するためのインドリン−2−オン誘導体 |
MA43159B1 (fr) | 2015-11-06 | 2020-08-31 | Hoffmann La Roche | Dérivés d'indoline-2-one |
JP2022550463A (ja) | 2019-10-01 | 2022-12-01 | エンピリアン ニューロサイエンス, インコーポレイテッド | トリプタミン発現を調整する真菌の遺伝子操作 |
EP4143158A1 (en) * | 2020-04-29 | 2023-03-08 | Basf Se | Preparation of aromatic carboxyamides by palladium-catalyzed carbonylation reaction |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3932953A1 (de) * | 1989-10-03 | 1991-04-11 | Boehringer Mannheim Gmbh | Neue 2-bicyclo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
DE3935514A1 (de) | 1989-10-25 | 1991-05-02 | Boehringer Mannheim Gmbh | Neue bicyclo-imidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
TW251284B (zh) | 1992-11-02 | 1995-07-11 | Pfizer | |
DE4427648A1 (de) | 1994-08-04 | 1996-02-08 | Basf Ag | N-Stubstituierte 3-Azabicyclo[3,2,0,]heptan-Derivate, ihre Herstellung und Verwendung |
FR2757157B1 (fr) | 1996-12-13 | 1999-12-31 | Sanofi Sa | Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant |
AU8438798A (en) | 1997-06-16 | 1999-01-04 | Janssen Pharmaceutica N.V. | Use of draflazine-analogues for treating pain |
WO2000040581A1 (en) | 1999-01-07 | 2000-07-13 | American Home Products Corporation | 3,4-dihydro-2h-benzo[1,4]oxazine derivatives |
IT1318403B1 (it) | 2000-03-17 | 2003-08-25 | Cooperativa Ct Ricerche Poly T | Esteri polisaccaridici di n-derivati di acido glutammico. |
AU2001249397A1 (en) | 2000-03-24 | 2001-10-08 | Cor Therapeutics, Inc. | Oxindole inhibitors of factor xa |
FR2807038B1 (fr) | 2000-04-03 | 2002-08-16 | Sanofi Synthelabo | Nouveaux derives d'indolin-2-one, leur preparation et les compositions pharmaceutiques les contenant |
AU7388701A (en) | 2000-06-29 | 2002-01-08 | Neurosearch As | Use of 3-substituted oxindole derivatives as kcnq potassium channel modulators |
US6524302B2 (en) | 2001-04-26 | 2003-02-25 | Scimed Life Systems, Inc. | Multi-lumen catheter |
AU2003300124A1 (en) | 2002-12-31 | 2004-07-29 | BUOLAMWINI, John, K | Novel nucleoside transport inhibitors |
NZ551543A (en) * | 2004-05-11 | 2009-12-24 | Egis Gyogyszergyar Nyrt | Pyridine derivatives of alkyl oxindoles as 5-HT7 receptor active agents |
ATE374202T1 (de) | 2004-06-29 | 2007-10-15 | Gruenenthal Gmbh | Neue analoga von nitrobenzylthioinosin |
US20060253263A1 (en) | 2005-04-11 | 2006-11-09 | Meshkin Brian J | Method to optimize drug selection, dosing and evaluation and to help predict therapeutic response and toxicity from immunosuppressant therapy |
AR053713A1 (es) * | 2005-04-20 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos heterociclicos y sus usos como agentes terapeuticos |
AR056317A1 (es) | 2005-04-20 | 2007-10-03 | Xenon Pharmaceuticals Inc | Compuestos de oxindol y composicion farmaceutica |
EP1904483A1 (en) | 2005-07-13 | 2008-04-02 | F. Hoffmann-Roche AG | Benzimidazole derivatives as 5-ht6,5-ht24 |
WO2007098214A1 (en) * | 2006-02-21 | 2007-08-30 | Amgen Inc. | Cinnoline derivatives as phosphodiesterase 10 inhibitors |
WO2007103373A2 (en) | 2006-03-07 | 2007-09-13 | Combinatorx, Incorporated | Compositions and methods for the treatment of immunoinflammatory disorders |
JP2009541493A (ja) | 2006-06-26 | 2009-11-26 | ヘリコン セラピューティクス,インコーポレイテッド | ガラニン−3レセプターアンタゴニストの使用による神経突起伸長の調節方法 |
US7952109B2 (en) | 2006-07-10 | 2011-05-31 | Alcatel-Lucent Usa Inc. | Light-emitting crystal structures |
WO2008046083A2 (en) | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Use of oxindole compounds as therapeutic agents |
PE20081401A1 (es) * | 2006-12-28 | 2008-10-24 | Hoffmann La Roche | Derivados de indol como antagonistas de receptores vasopresina |
RS52700B (en) | 2006-12-30 | 2013-08-30 | Abbott Gmbh & Co. Kg | SUBSTITUTED OXINDOL DERIVATIVE AND ITS USE AS A VASOPRESIN RECEPTOR LIGAND |
UY30846A1 (es) | 2006-12-30 | 2008-07-31 | Abbott Gmbh & Amp | Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos |
WO2009018275A1 (en) | 2007-07-30 | 2009-02-05 | University Of Rochester | Adenosine and its mimetics, modulators, transport inhibitors, and receptor agonists as a therapeutic tool to replace or improve the efficacy of deep brain stimulation |
JO3126B1 (ar) | 2007-11-14 | 2017-09-20 | Janssen Pharmaceutica Nv | مثبطات ناقل نيوكليوسيد متوازن اي ان تي 1 |
EP2219666A4 (en) | 2007-11-15 | 2011-05-25 | Univ North Carolina | PROSTATE ACID PHOSPHATASE FOR THE TREATMENT OF PAIN |
EP2108641A1 (en) * | 2008-04-11 | 2009-10-14 | Laboratorios Almirall, S.A. | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors |
EP2113503A1 (en) | 2008-04-28 | 2009-11-04 | Laboratorios Almirall, S.A. | New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors |
JO3265B1 (ar) | 2008-12-09 | 2018-09-16 | Novartis Ag | مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض |
ES2583086T3 (es) * | 2011-04-21 | 2016-09-19 | Bayer Intellectual Property Gmbh | Pirazolopiridinas sustituidas con fluoroalquilo y su uso |
EP2838538B1 (en) * | 2012-04-20 | 2017-03-15 | Annji Pharmaceutical Co., Ltd. | Cyclopropanecarboxylate esters of purine analogues |
AU2013314417B2 (en) | 2012-09-13 | 2016-01-21 | F. Hoffmann-La Roche Ag | 2-oxo-2,3-dihydro-indoles for the treatment of CNS disorders |
CA2915536C (en) | 2013-06-19 | 2021-10-19 | F. Hoffmann-La Roche Ag | Indolin-2-one or pyrrolo-pyridin/pyrimidin-2-one derivatives |
EP3160957B1 (en) | 2014-06-26 | 2018-06-06 | F. Hoffmann-La Roche AG | Indolin-2-one or pyrrolo-pyridin-2-one derivatives |
MA41841A (fr) | 2015-03-30 | 2018-02-06 | Global Blood Therapeutics Inc | Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs |
CA3001873A1 (en) | 2015-11-06 | 2017-05-11 | Neurocrine Biosciences, Inc. | N-[2-(1-benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1-carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurologicaldiseases |
KR20180080262A (ko) | 2015-11-06 | 2018-07-11 | 사뮤메드, 엘엘씨 | 골관절염의 치료 |
JP6857653B2 (ja) | 2015-11-06 | 2021-04-14 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Cns及び関連障害の治療において使用するためのインドリン−2−オン誘導体 |
MA43159B1 (fr) | 2015-11-06 | 2020-08-31 | Hoffmann La Roche | Dérivés d'indoline-2-one |
EP3371170B1 (en) | 2015-11-06 | 2019-07-31 | H. Hoffnabb-La Roche Ag | Indolin-2-one derivatives useful in the treatment of cns diseases |
CN108137561B (zh) | 2015-11-06 | 2021-03-26 | 豪夫迈·罗氏有限公司 | 二氢吲哚-2-酮衍生物 |
-
2016
- 2016-11-02 MA MA43159A patent/MA43159B1/fr unknown
- 2016-11-02 RS RS20200807A patent/RS60504B1/sr unknown
- 2016-11-02 UA UAA201806057A patent/UA122589C2/uk unknown
- 2016-11-02 MX MX2018005121A patent/MX2018005121A/es unknown
- 2016-11-02 CN CN201680064831.2A patent/CN108349944B/zh active Active
- 2016-11-02 PT PT167887058T patent/PT3371168T/pt unknown
- 2016-11-02 ES ES16788705T patent/ES2808920T3/es active Active
- 2016-11-02 MY MYPI2018000647A patent/MY197370A/en unknown
- 2016-11-02 SG SG11201803796SA patent/SG11201803796SA/en unknown
- 2016-11-02 HU HUE16788705A patent/HUE050083T2/hu unknown
- 2016-11-02 SI SI201630857T patent/SI3371168T1/sl unknown
- 2016-11-02 AU AU2016348493A patent/AU2016348493B2/en active Active
- 2016-11-02 KR KR1020187015975A patent/KR20180080305A/ko not_active Application Discontinuation
- 2016-11-02 RU RU2018120703A patent/RU2727179C2/ru active
- 2016-11-02 BR BR112018008056A patent/BR112018008056A2/pt active Search and Examination
- 2016-11-02 WO PCT/EP2016/076332 patent/WO2017076852A1/en active Application Filing
- 2016-11-02 LT LTEP16788705.8T patent/LT3371168T/lt unknown
- 2016-11-02 CR CR20180255A patent/CR20180255A/es unknown
- 2016-11-02 PE PE2018000537A patent/PE20181885A1/es unknown
- 2016-11-02 DK DK16788705.8T patent/DK3371168T3/da active
- 2016-11-02 PL PL16788705T patent/PL3371168T3/pl unknown
- 2016-11-02 JP JP2018541528A patent/JP6857662B2/ja active Active
- 2016-11-02 CA CA3002489A patent/CA3002489C/en active Active
- 2016-11-02 EP EP16788705.8A patent/EP3371168B1/en active Active
- 2016-11-04 TW TW105135901A patent/TWI631117B/zh active
- 2016-11-04 AR ARP160103363A patent/AR106588A1/es unknown
-
2018
- 2018-04-12 IL IL258656A patent/IL258656A/en active IP Right Grant
- 2018-04-12 ZA ZA2018/02411A patent/ZA201802411B/en unknown
- 2018-04-24 CL CL2018001085A patent/CL2018001085A1/es unknown
- 2018-05-04 PH PH12018500978A patent/PH12018500978A1/en unknown
- 2018-05-04 US US15/971,323 patent/US10710985B2/en active Active
- 2018-05-30 CO CONC2018/0005718A patent/CO2018005718A2/es unknown
- 2018-12-13 HK HK18116051.2A patent/HK1257170A1/zh unknown
-
2020
- 2020-06-10 US US16/897,879 patent/US11066393B2/en active Active
- 2020-07-23 HR HRP20201158TT patent/HRP20201158T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1255045A1 (zh) | 取代的氧代吡啶衍生物 | |
IL248550B (en) | History of indoline-2-one or pyrrolo-pyridin-2-one | |
IL253381A0 (en) | History of h9-pyrrolo-dipyridine | |
HK1257170A1 (zh) | 二氫吲哚-2-酮衍生物 | |
HUE050450T2 (hu) | Fluoralkil-fluorén-származékok | |
IL248773A0 (en) | History of naphthyridinedione | |
IL248629B (en) | Substances containing diheteroaryl conjugated to cycloalkyl and their uses | |
PL3164393T3 (pl) | Pochodne flawaglin | |
IL251005B (en) | Pyrido-oxazinone derivatives | |
PL3119744T3 (pl) | Pochodne 2-cyjano-3-cyklopropylo-3-hydroksy-N-arylo-tioakryloamidu | |
HK1243705A1 (zh) | 吲哚衍生物 |